Skip to main content
Premium Trial:

Request an Annual Quote

Advinus to Use Corning's Epic Technology in India

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Indian therapeutics and drug development services firm Advinus Therapeutics will collaborate with Corning to offer Corning's Epic label-free detection services in India.

Under the agreement, Pune-based Advinus will use the Epic technology in its drug discovery capabilities and to provide assay development and screening services in India and abroad. Financial and other terms were not disclosed.

The Corning detection technology is used to identify targets, pathways, and interactions, providing data for use in drug development.

"This collaboration highlights the growing adoption of label-free technology and the biological insights it enables in drug discovery research," Ron Verkleeren, director of advanced life sciences for Corning, said in a statement. "We believe this is an important step forward in making our Epic technology more accessible to life science researchers worldwide."

Advinus offers end-to-end development services, is developing its own drug candidates, and in its center in Bangalore provides pre-clinical and early clinical drug development services.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.